8-K: TOMI Reports Q3 2025 Results, Eyes Growth & Capital Flexibility

TOMI Environmental Solutions announced Q3 2025 financial results, showing strong sequential revenue growth and strategic initiatives for future expansion, alongside plans for capital access.

Summary

• Q3 2025 revenue was $2.0 million, reflecting a 95% sequential increase over Q2 2025.
• Gross profit margin remained healthy at 61% in Q3 2025.
• Operating loss for Q3 2025 was $(321,000), compared to income from operations of $149,000 in Q3 2024.
• Net loss for Q3 2025 was $(450,000) or $(0.02) per basic and diluted share, compared to net income of $59,000 or $0.00 per share in Q3 2024.
• Year-to-date (nine months) revenue was $4.6 million, compared to $6.7 million for the same period in 2024.
• Year-to-date operating loss was $(2.2 million), compared to $(956,000) for the same period in 2024.
• Year-to-date net loss was $(1.9 million) or $(0.10) per basic and diluted share, compared to $(1.2 million) or $(0.06) per share for the same period in 2024.
• Sales order backlog grew to $0.9 million at quarter-end and further expanded to $1.3 million as of October 31, with approximately $3 million in pending contracts expected to close before year-end.
• Estimated potential demand for TOMI's three product offerings totals approximately $15 million, of which $7 million are designated as high priority.
• Working capital was $2.5 million as of September 30, 2025.
• Cash used in operations improved by approximately $876,000 for the nine months ended September 30, 2025, compared to the same period in 2024.

Sentiment

Score: 6

Explanation: The company shows strong sequential revenue growth and positive strategic developments, including backlog expansion, new installations, and regulatory tailwinds. However, these positives are tempered by significant year-over-year declines in revenue and profitability, indicating ongoing challenges. The capital raise plans provide financial flexibility but also suggest a need for external funding and potential dilution.

Positives

• Achieved a 95% sequential revenue increase in Q3 2025 over Q2 2025, reaching $2.0 million.
• Maintained a strong gross profit margin of 61% in Q3 2025, underscoring operational efficiency.
• Reduced selling, research, and administrative expenses year-to-date, demonstrating disciplined cost management.
• Increased international revenue contribution to nearly 36% of Q3 revenue, up from 20% in Q2 2025.
• SteraMist solution sales increased 21% year-over-year for the nine months ended September 30, 2025.
• Sales order backlog grew to $0.9 million at quarter-end and further expanded to $1.3 million as of October 31, with approximately $3 million in pending contracts expected to close before year-end.
• Estimated potential demand for product offerings totals approximately $15 million, with $7 million designated as high priority.
• Completed major SteraMist installations and successfully launched the new SteraMist Integration System – Standalone (SIS-SA) in the life sciences sector.
• The FDA broadened the permitted use of Hydrogen Peroxide, significantly expanding the potential application of SteraMist iHP.
• Onboarded three major service provider companies in Q3, showing strong potential for expanded use of SteraMist iHP technology.
• Secured a $175,000 purchase of SteraMist iHP equipment and BIT Solution by a premier decontamination services provider with 18 franchises.
• Cash used in operations improved by approximately $876,000 for the nine months ended September 30, 2025, compared to the same period in 2024.
• Successfully completed a $535,000 convertible note financing during 2025 to provide additional working capital.
• Entered into an equity line of credit on November 5, 2025, for up to $20,000,000 of common stock over a 24-month period.
• Expects to file a universal shelf registration statement on Form S-3 for up to $50,000,000 in securities, providing financial flexibility.

Negatives

• Net sales for Q3 2025 decreased to $2,012,000 from $2,542,000 in Q3 2024, representing a 20.9% year-over-year decline.
• Net sales for the nine months ended September 30, 2025, decreased to $4,619,000 from $6,670,000 in the same period of 2024, a 30.7% year-over-year decline.
• Operating loss for Q3 2025 was $(321,000), a significant decline from operating income of $149,000 in Q3 2024.
• Operating loss for the nine months ended September 30, 2025, increased to $(2,209,000) from $(956,000) in the same period of 2024.
• Net loss for Q3 2025 was $(450,000) or $(0.02) per share, compared to net income of $59,000 or $0.00 per share in Q3 2024.
• Net loss for the nine months ended September 30, 2025, increased to $(1,943,000) or $(0.10) per share, from $(1,221,000) or $(0.06) per share in the same period of 2024.
• Total current assets decreased to $5,030,309 at September 30, 2025, from $6,493,113 at December 31, 2024.
• Total assets decreased to $8,045,191 at September 30, 2025, from $9,693,738 at December 31, 2024.
• Accumulated deficit increased to $(56,246,448) at September 30, 2025, from $(54,302,991) at December 31, 2024.

Risks

• Ability to acquire new customers and expand sales.
• Ability to maintain and manage growth and generate sales.
• Reliance on a single or a few products for a majority of revenues.
• General business and economic conditions.
• Unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from forward-looking statements.
• Other risks as described in SEC filings, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company anticipates strong operational momentum into Q4 2025 and throughout 2026, driven by expanding recurring sales, a growing customer base, and strategic positioning in clean manufacturing, AI-enabled automation, and biosecurity. Key initiatives include expanding recurring service contracts, increasing SteraMist solution sales, growing international presence, pursuing government and institutional partnerships, strengthening the balance sheet, and enhancing the corporate team. An OEM partnership is expected to yield its first collaborative installation in Q4 2025, and EU/UK regulatory approvals are pending for international distributors.

Management Comments

• "In the third quarter, we delivered a 95% sequential revenue increase, expanding our recurring BIT Solution sales and securing new customer partnerships across critical industries, showcasing the strength of our strategy and execution."
• "Our technology continues to gain recognition, including SteraMist being named Disinfection and Decontamination Products Company of the Year 2025."
• "With the FDA’s expanded approval for hydrogen peroxide use and demonstrated success combating Honeybee Colony Collapse, TOMI is broadening its reach into food, agriculture, and environmental biosecurity markets—key long-term growth drivers."
• "Looking ahead, our OEM partnership with a leading player is accelerating its reach into high-containment and cleanroom markets, with the first collaborative installation expected in Q4 2025."
• "Internationally, TOMI’s distributors in Germany, the Netherlands, and Italy are advancing strong pipelines pending final EU and UK regulatory approvals, which are expected to further expand global market penetration."
• "Our growing backlog and expanding pipeline give us confidence in our ability to maintain momentum into the fourth quarter and throughout 2026."

Industry Context

TOMI operates within the global disinfection and decontamination market, leveraging its Binary Ionization Technology (BIT) platform. The company is strategically positioned to capitalize on global trends in clean manufacturing, AI-enabled automation, and biosecurity. The FDA's broadened approval for hydrogen peroxide use is a significant industry development that expands the potential applications for SteraMist iHP. The company also notes its technology's success in combating Honeybee Colony Collapse, indicating expansion into agriculture and environmental biosecurity. SteraMist was recognized as 'Disinfection and Decontamination Products Company of the Year 2025', highlighting its standing in the industry.

Comparison to Industry Standards

• SteraMist was named 'Disinfection and Decontamination Products Company of the Year 2025,' indicating strong industry recognition and competitive positioning.
• The FDA's broadened permitted use of Hydrogen Peroxide is a favorable regulatory development that expands the market potential for TOMI's SteraMist iHP technology, aligning with broader industry trends towards effective and safe disinfection solutions.
• The company is forming an OEM partnership with a 'leading player' to accelerate reach into high-containment and cleanroom markets, suggesting collaboration with established industry leaders.
• International distributors in Germany, the Netherlands, and Italy are advancing pipelines pending EU and UK regulatory approvals, indicating efforts to meet global benchmarks and expand market share in highly regulated regions.
• The company's focus on recurring BIT Solution sales and expanding service contracts aligns with a common industry strategy to build stable revenue streams, similar to other technology and service providers.

Stakeholder Impact

• Shareholders: Potential for dilution from the equity line of credit and shelf registration, but also potential for long-term value creation through strategic growth initiatives and improved financial flexibility.
• Customers: Benefit from continued product innovation (SteraMist Integration System – Standalone), expanded applications (FDA ruling), and a growing network of certified service providers.
• Employees: Potential for growth and expansion of the corporate team, but also pressure for disciplined cost management.
• Creditors: Convertible note financing and improved cash used in operations indicate efforts to manage liquidity, while the equity line of credit provides additional financial backing.

Next Steps

• First collaborative installation with an OEM partner expected in Q4 2025.
• Advancing strong pipelines with international distributors pending final EU and UK regulatory approvals.
• Executing a focused strategy to expand recurring service contracts and explore new product lines.
• Driving year-on-year recurring revenue growth by increasing SteraMist solution sales.
• Continuing to grow international presence through targeted marketing and referral business.
• Pursuing additional government and institutional partnerships.
• Strengthening balance sheet flexibility through disciplined financial management.
• Strengthening the corporate team to support growth.
• Filing a universal shelf registration statement on Form S-3.

Key Dates

Recommendation

While TOMI Environmental Solutions demonstrated strong sequential revenue growth in Q3 2025 and has promising strategic initiatives, including a growing backlog, new product installations, and favorable regulatory developments, the year-over-year financial performance shows significant declines in revenue and profitability. The company is actively addressing liquidity through a convertible note, an equity line of credit, and a shelf registration, which provides necessary capital but also introduces potential for shareholder dilution. Given the mixed financial results—strong sequential recovery versus persistent year-over-year losses—and the need for external capital, a 'hold' recommendation is appropriate. Investors should monitor the execution of growth strategies, the impact of capital raises, and progress towards sustained profitability before making further investment decisions.

Keywords

TOMI Environmental Solutions, SteraMist, Binary Ionization Technology, disinfection, decontamination, iHP, life sciences, healthcare, food safety, commercial markets, biosecurity, Q3 2025 earnings, financial results, SEC filing, NASDAQ: TOMZ